|
Jul 29
|
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Jul 29
|
Wall Street is still jittery on GLP-1s
|
|
Jul 29
|
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
|
|
Jul 29
|
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
|
|
Jul 29
|
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
|
|
Jul 29
|
Novo Nordisk A/S – Share repurchase programme
|
|
Jul 29
|
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
|
|
Jul 29
|
Zacks Market Edge Highlights: LLY and NVO
|
|
Jul 28
|
This Could Send Ozempic's Sales Potential to a Whole Other Level
|
|
Jul 27
|
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
|
|
Jul 26
|
June PCE inflation print, auto earnings: Morning Brief
|
|
Jul 26
|
EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
|
|
Jul 26
|
Is Eli Lilly's Stock in a Bubble?
|
|
Jul 26
|
EU approves Novo Nordisk's Wegovy for heart, stroke treatment
|
|
Jul 26
|
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
|
|
Jul 25
|
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
|
|
Jul 25
|
Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk
|
|
Jul 25
|
Why Viking’s Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
|
|
Jun 24
|
Crypto under pressure, Good Buy or Goodbye: Market Domination
|
|
Jun 24
|
Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs
|